- AutorIn
- Gin S. Malhi Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia#CADE Clinic and Mood‑T, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, Australia#Department of Psychiatry, University of Oxford, Oxford, UK
- Erica BellAcademic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia#CADE Clinic and Mood‑T, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, Australia
- Maedeh JadidiAcademic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia#CADE Clinic and Mood‑T, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, Australia
- Michael Gitlin
- Michael Bauer
- Titel
- Countering the declining use of lithium therapy
- Untertitel
- a call to arms
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-936050
- Quellenangabe
- International Journal of Bipolar Disorders
Erscheinungsjahr: 2023
Jahrgang: 11
E-ISSN: 2194-7511
Artikelnummer: 30 - Erstveröffentlichung
- 2023
- Abstract (EN)
- For over half a century, it has been widely known that lithium is the most efficacious treatment for bipolar disorder. Yet, despite this, its prescription has consistently declined over this same period of time. A number of reasons for this apparent disparity between evidence and clinical practice have been proposed, including a lack of confidence amongst clinicians possibly because of an absence of training and lack of familiarity with the molecule. Simultaneously, competition has grown within the pharmacological armamentarium for bipolar disorder with newer treatments promoting an image of being safer and easier to prescribe primarily because of not necessitating plasma monitoring, which understandably is appealing to patients who then exercise their preferences accordingly. However, these somewhat incipient agents are yet to reach the standard lithium has attained in terms of its efficacy in providing prophylaxis against the seemingly inevitable recrudescence of acute episodes that punctuates the course of bipolar disorder. In addition, none of these mimics have the additional benefits of preventing suicide and perhaps providing neuroprotection. Thus, a change in strategy is urgently required, wherein myths regarding the supposed difficulties in prescribing lithium and the gravity of its side-effects are resolutely dispelled. It is this cause to which we have pledged our allegiance and it is to this end that we have penned this article.
- Andere Ausgabe
- Link zum Artikel, der zuerst in der Zeitschrift „International Journal of Bipolar Disorders” im Springer Verlag erschienen ist.
DOI: 10.1186/s40345-023-00310-x - Freie Schlagwörter (DE)
- Lithiumtherapie, bipolare Störung, Diskrepanz zwischen Evidenz und klinischer Praxis, Strategiewechsel
- Freie Schlagwörter (EN)
- lithium therapy, bipolar disorder, disparity between evidence and clinical practice, change in strategy
- Klassifikation (DDC)
- 610
- Verlag
- Springer, Berlin [u. a.]
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:14-qucosa2-936050
- Veröffentlichungsdatum Qucosa
- 19.09.2024
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
CC BY 4.0